Publication: Ecancer Medicalscience

First reported 16 hours ago - Updated 22 mins ago - 1 reports

Patient tumour characteristics for high-mitotic rate melanoma

The tumour characteristic known as mitotic rate (measure of cell division) has been connected with prognosis and survival in melanoma patients.However, the literature is scarce regarding the clinical presentation of high-mitotic rate melanoma, which could ... [Published Ecancer Medicalscience - 16 hours ago]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Myc inhibition is an effective therapeutic strategy against the most aggressive of all brain tumours

Research led by the Vall d’Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma – a highly agressive tumour type that notoriously outsmarts current anti-cancer ... [Published Ecancer Medicalscience - Aug 19 2014]
Entities: Tumor, glioma, Strategy, Cancer
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Death rates in top four cancer killers fall by a third over twenty years

Death rates for breast, bowel, lung and prostate cancer combined have fallen by almost a third (30 percent) in the last 20 years according to the latest Cancer Research UK figures.The figures 1 during this period highlight how research has had a powerful ... [Published Ecancer Medicalscience - Aug 18 2014]
First reported Aug 17 2014 - Updated Aug 18 2014 - 1 reports

Microchip reveals how tumour cells transition to invasion

Using a microengineered device that acts as an obstacle course for cells, researchers have shed new light on a cellular metamorphosis thought to play a role in tumour cell invasion throughout the body.The epithelial-mesenchymal transition (EMT) is a process ... [Published Ecancer Medicalscience - Aug 17 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Cetuximab delivers better overall survival than bevacizumab in metastatic colorectal cancer

by ecancer reporter Janet FrickerPatients with KRAS exon 2 wild type metastatic colorectal cancer achieve longer overall survival with FOLFIRI plus cetuximab than FOLFIRI plus bevacizumab, concluded the FIRE-3 trial published in Lancet Oncology .While ... [Published Ecancer Medicalscience - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

New ‘portal’ identified for drug delivery

by ecancer reporter Janet FrickerIn a study published in Nature Medicine US scientists have identified a cellular portal at the blood tumour interface in rodents that enables active pumping of antibodies and agents from the blood directly into solid ... [Published Ecancer Medicalscience - Aug 18 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

NICE rejects abiraterone for advanced prostate cancer pre-chemotherapy

The Institute of Cancer Research gives a comment on NICE's decision:Commenting on today’s rejection of abiraterone before chemotherapy in final draft guidance from NICE, Professor Paul Workman, Interim Chief Executive of The Institute of Cancer Research, ... [Published Ecancer Medicalscience - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

No difference in response rate but overall survival benefit with first-line FOLFIRI/cetuximab versus FOLFIRI/bevacizumab in metastic colocrectal cancer

There was no difference in response rate for FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab.In a European phase III FIRE-3 trial reported in The Lancet Oncology, Heinemann et al found no difference in response rate, the primary endpoint, between FOLFIRI ... [Published Ecancer Medicalscience - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

New scheme launched to bring together engineers, physicists and biologists

A new funding scheme launched by Cancer Research UK looks to bring new insight to some of cancer’s biggest challenges.The Cancer Research UK Multidisciplinary Project Award will fund projects that encourage collaborations between cancer researchers and ... [Published Ecancer Medicalscience - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Case Report: Interpretation of PET/CT findings in patients with advanced lung cancer who have undergone pleurodesis

2 / DOI: 10.3332/ecancer.2014.452Case ReportMarcus Paulo Fernandes Amarante, Riad Naim Younes, Letícia Rigo and Marcelo Rocha de Sousa CruzA consensus has not yet been reached for the ideal moment to carry out pleurodesis in patients with malignant pleural ... [Published Ecancer Medicalscience - Aug 12 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

New Europe-wide scheme launched to improve cancer services

In 2012, 3.45 million people were diagnosed with cancer and 1.75 million died of cancer.With an ageing population, the burden that cancer will impose on our societies will increase.Cancer has replaced cardiovascular disease as the leading cause of premature ... [Published Ecancer Medicalscience - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

US lung cancer rates vary by subtype, sex, race/ethnicity, and age

A new analysis confirms that US lung cancer rates are declining overall, but it also uncovers previously unrecognised trends related to cancer subtype, sex, race/ethnicity, and age.Published early online in Cancer , the findings provide a more accurate ... [Published Ecancer Medicalscience - Aug 11 2014]

Quotes

"The results from this single-centre study merit replication elsewhere to confirm generalisability and to further explore the potential implications for detection and treatment of at-risk patients, who in this study were found to have a distinct phenotypic and historical profile. Mitotically active melanomas were more often seen in older men with chronic solar field damage. These tumours have a predilection for the head and neck and can present with nodular structure and amelanosis. Such atypical clinical features may pose a challenge to timely detection; thus a high index of suspicion is warranted when the patient reports a history of morphologic change and rapid growth."
"People are really interested in how EMT works and how it might be associated with tumour spread, but nobody has been able to see how it happens" said lead author Ian Y Wong, assistant professor in the Brown SchoolBrown School of Engineering and the Center for Biomedical Engineering, who performed...
"Basal-like breast cancers are as different from luminal breast cancers as they are from lung cancers" he said

More Content

All (43) | News (43) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Patient tumour characteristics for high-mitotic... [Published Ecancer Medicalscience - 16 hours ago]
Myc inhibition is an effective therapeutic stra... [Published Ecancer Medicalscience - Aug 19 2014]
Cetuximab delivers better overall survival than... [Published Ecancer Medicalscience - Aug 18 2014]
New ‘portal’ identified for drug delivery [Published Ecancer Medicalscience - Aug 18 2014]
Death rates in top four cancer killers fall by ... [Published Ecancer Medicalscience - Aug 18 2014]
Microchip reveals how tumour cells transition t... [Published Ecancer Medicalscience - Aug 17 2014]
NICE rejects abiraterone for advanced prostate ... [Published Ecancer Medicalscience - Aug 15 2014]
No difference in response rate but overall surv... [Published Ecancer Medicalscience - Aug 14 2014]
New scheme launched to bring together engineers... [Published Ecancer Medicalscience - Aug 14 2014]
Case Report: Interpretation of PET/CT findings ... [Published Ecancer Medicalscience - Aug 12 2014]
New Europe-wide scheme launched to improve canc... [Published Ecancer Medicalscience - Aug 12 2014]
US lung cancer rates vary by subtype, sex, race... [Published Ecancer Medicalscience - Aug 11 2014]
Cancer study reveals powerful new system for cl... [Published Ecancer Medicalscience - Aug 07 2014]
Policy: NHS reforms in England: the implication... [Published Ecancer Medicalscience - Aug 05 2014]
'Guardian' protein may also encourage the sprea... [Published Ecancer Medicalscience - Aug 05 2014]
AACR commends FDA on actions to protect public ... [Published Ecancer Medicalscience - Aug 05 2014]
European Medicines Agency approves lenvatinib f... [Published Ecancer Medicalscience - Jul 31 2014]
Study identifies rational drug combinations tha... [Published Ecancer Medicalscience - Jul 31 2014]
Cause of rare childhood cancer discovered [Published Ecancer Medicalscience - Jul 31 2014]
Minor sub-clones of cancer cells drive tumour g... [Published Ecancer Medicalscience - Jul 30 2014]
Research: Anaplastic thyroid cancer: multimodal... [Published Ecancer Medicalscience - Jul 30 2014]
New study finds that stem cells are far more be... [Published Ecancer Medicalscience - Jul 29 2014]
New treatment combination benefited patients wi... [Published Ecancer Medicalscience - Jul 29 2014]
New accurate epigenetic test could eliminate un... [Published Ecancer Medicalscience - Jul 28 2014]
FDA approves idelalisib for the treatment of pa... [Published Ecancer Medicalscience - Jul 25 2014]
NICE recommends single does intrabeam radiother... [Published Ecancer Medicalscience - Jul 25 2014]
Research: Clinicopathologic subtypes and compro... [Published Ecancer Medicalscience - Jul 24 2014]
Does cycling increase prostate cancer risk? [Published Ecancer Medicalscience - Jul 23 2014]
New genetic loci associated with breast cancer ... [Published Ecancer Medicalscience - Jul 22 2014]
Case Report: Spindle cell carcinoma of the tong... [Published Ecancer Medicalscience - Jul 22 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.